 Home > Active Ingredient News > Endocrine System > JAMA: The latest evidence report on screening for gestational diabetes.

JAMA: The latest evidence report on screening for gestational diabetes.

 Last Update: 2021-10-20
 Source: Internet
 Author: User

Tags

senokot pregnancy

81 periodic table

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

Importance: Gestational diabetes is associated with several adverse health outcomes
.

Gestational diabetes is associated with several adverse health outcomes
.

Purpose: To update the 2012 review of gestational diabetes screening
.

Main results and measures: pregnancy, fetal/newborn and long-term health outcomes; screening hazards; accuracy
.

Results: A total of 76 studies were included (18 randomized clinical trials [n = 31 241], 2 non-randomized intervention studies [n = 190], 56 observational studies [n = 261 678])

Table 1 Summary of treated and untreated trials at 24 weeks of pregnancy or longer

Table 2 Meta-analysis of trials: pre-eclampsia, gestational diabetes treated and untreated

Results: The direct evidence of screening vs.
non-screening is still limited
.

There is no significant correlation between one-step and two-step screening and improving health prognosis

Direct evidence of screening vs.

Pillay J, Donovan L, Guitard S,et al.

Leave a message here

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

Related Products

USA/EU/AU warehouse supply Norethindrone CAS 68-22-4 99% Purity 19-NOR-4-ANDROSTEN-17-ALPHA-ETHYNYL-17-BETA-OL-3-ONE

CAS No.: 68-22-4

Pharmacy Grade

$5-6/KG FOB

Bicalutamide 40% white powder CAS 90357-06-5

CAS No.: 90357-06-5

Pharmacy Grade

$4-5/G FOB

L-Thyroxine CAS 51-48-9

CAS No.: 51-48-9

Pharmacy Grade

$88-98/KG FOB

Hot Tags

united states jobs(223)

jobs united states(236)

1 year treasury(277)

1 year subscription(296)

announcements today(81)

80 20 company(94)

united states logo(227)

single use technology(195)

healthy food name(42)

ups united states(221)

Hot Articles

The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.